190 related articles for article (PubMed ID: 9797219)
1. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.
Blagburn BL; Drain KL; Land TM; Kinard RG; Moore PH; Lindsay DS; Patrick DA; Boykin DW; Tidwell RR
Antimicrob Agents Chemother; 1998 Nov; 42(11):2877-82. PubMed ID: 9797219
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
Baishanbo A; Gargala G; Duclos C; François A; Rossignol JF; Ballet JJ; Favennec L
J Antimicrob Chemother; 2006 Feb; 57(2):353-5. PubMed ID: 16361328
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
4. Dicationic furans inhibit development of Cryptosporidium parvum in HSD/ICR suckling Swiss mice.
Blagburn BL; Drain KL; Land TM; Moore PH; Kinard RG; Lindsay DS; Kumar A; Shi J; Boykin DW; Tidwell RR
J Parasitol; 1998 Aug; 84(4):851-6. PubMed ID: 9714224
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves.
Schnyder M; Kohler L; Hemphill A; Deplazes P
Vet Parasitol; 2009 Mar; 160(1-2):149-54. PubMed ID: 19062195
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis.
Giacometti A; Burzacchini F; Cirioni O; Barchiesi F; Dini M; Scalise G
Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):885-9. PubMed ID: 10691200
[TBL] [Abstract][Full Text] [Related]
7. The immunomodulatory activity of secnidazole-nitazoxanide in a murine cryptosporidiosis model.
Madbouly N; El Amir A; Abdel Kader A; Rabee I; Farid A
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33625354
[No Abstract] [Full Text] [Related]
8. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model.
Perrucci S; Fichi G; Buggiani C; Rossi G; Flamini G
Parasitol Res; 2006 Jul; 99(2):184-8. PubMed ID: 16547730
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Vet Parasitol; 2018 Jan; 250():7-14. PubMed ID: 29329627
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.
Theodos CM; Griffiths JK; D'Onfro J; Fairfield A; Tzipori S
Antimicrob Agents Chemother; 1998 Aug; 42(8):1959-65. PubMed ID: 9687390
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum.
Healey MC; Yang S; Rasmussen KR; Jackson MK; Du C
J Parasitol; 1995 Feb; 81(1):114-6. PubMed ID: 7876965
[TBL] [Abstract][Full Text] [Related]
12. Curcumin: A promising treatment for Cryptosporidium parvum infection in immunosuppressed BALB/c mice.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Exp Parasitol; 2018 Dec; 195():59-65. PubMed ID: 30385266
[TBL] [Abstract][Full Text] [Related]
13. Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs.
Viu M; Quílez J; Sánchez-Acedo C; del Cacho E; López-Bernad F
Vet Parasitol; 2000 Jun; 90(3):163-70. PubMed ID: 10841996
[TBL] [Abstract][Full Text] [Related]
14. Development of particulate drug formulation against C. parvum: Formulation, characterization and in vivo efficacy.
Blanco-García E; Guerrero-Callejas F; Blanco-Méndez J; Gómez-Couso H; Luzardo-Álvarez A
Eur J Pharm Sci; 2016 Sep; 92():74-85. PubMed ID: 27381880
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.
Li X; Brasseur P; Agnamey P; Leméteil D; Favennec L; Ballet JJ; Rossignol JF
Folia Parasitol (Praha); 2003 Mar; 50(1):19-22. PubMed ID: 12735719
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy for cryptosporidiosis in immunosuppressed mouse model.
Sanad MM; Al-Malki JS
J Egypt Soc Parasitol; 2007 Dec; 37(3):945-56. PubMed ID: 18383794
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.
Tzipori S; Rand W; Griffiths J; Widmer G; Crabb J
Clin Diagn Lab Immunol; 1994 Jul; 1(4):450-63. PubMed ID: 8556484
[TBL] [Abstract][Full Text] [Related]
18. Oral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDS.
de la Tribonnière X; Valette M; Alfandari S
Infection; 1999; 27(3):232. PubMed ID: 10378141
[No Abstract] [Full Text] [Related]
19. The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.
Lee S; Harwood M; Girouard D; Meyers MJ; Campbell MA; Beamer G; Tzipori S
PLoS One; 2017; 12(10):e0185906. PubMed ID: 28973041
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the prophylactic and therapeutic effects of paromomycin, recombinant IL-12 alone or in combination against Cryptosporidium parvum infection in immunosuppressed mice.
Gamra MM; el-Hosseiny LM
J Egypt Soc Parasitol; 2003 Apr; 33(1):109-22. PubMed ID: 12739805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
